As millions of people worldwide use Ozempic (semaglutide) for diabetes and weight reduction, researchers are racing to understand its full safety profile. While early clinical trials showed promising metabolic benefits, more recent case reports, observational studies, and post-marketing data have raised concerns about gastrointestinal disorders, pancreatic events, kidney issues, and potential long-term risks This page compiles the most notable scientific research, medical literature, safety concerns, and developing investigations into Ozempic.
Note: Research on long-term outcomes is ongoing. Several risks remain under active review as new data emerges.
Important Ozempic and GLP-1 studies and clinical research
May 21, 2026- Popular Diabetes Drugs May Help Slow the Spread of Certain Cancers, New Study Finds
A new study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting suggests that GLP-1 drugs — the same class of medications behind brands like Ozempic, Wegovy, and Mounjaro — may do more than manage blood sugar and weight. Researchers found that people with certain early-stage cancers who took these drugs were significantly less likely to see their cancer spread (or “metastasize”) to stage IV compared to people taking a different class of diabetes medication. The study team analyzed real-world health records for more than 12,000 people worldwide who had been diagnosed with stage I, II, or III cancer — meaning the cancer had not yet spread throughout the body. They looked at seven cancer types linked to obesity: breast, prostate, lung, colorectal, liver, kidney, and pancreatic cancer. Half of the patients in the study had started taking a GLP-1 drug after their cancer diagnosis (drugs such as semaglutide, tirzepatide, dulaglutide, and others in that family). The other half had started taking a gliptin instead. The researchers then compared how many people in each group went on to develop stage IV (metastatic) cancer. They also examined a separate set of genetic data to see whether the presence of “GLP-1 receptors” on tumor cells — essentially, docking stations that let GLP-1 drugs interact with the cancer — was connected to how long patients survived. For four of the seven cancer types, the results were striking. People taking GLP-1 drugs were 38% to 50% less likely to progress to stage IV cancer than people taking gliptins: Lung cancer: 10% of the GLP-1 group progressed, compared to 22% of the gliptin group Breast cancer: 10% vs. 20% Colorectal cancer: 13% vs. 22% Liver cancer: 19% vs. 28% For the other three cancers — prostate, pancreatic, and kidney — patients on GLP-1 drugs also had fewer cases of cancer spreading, but the difference wasn’t large enough to be considered statistically meaningful. Separately, the genetic analysis showed that tumors with more GLP-1 receptors were associated with a 33% lower risk of death overall, and a 45% lower risk specifically for breast cancer. In plain terms: cancers that are more “receptive” to GLP-1 signaling tend to behave less aggressively. Importantly, the study did not find higher rates of stomach or pancreas inflammation in the GLP-1 group — side effects that are sometimes associated with these drugs — even though people with cancer might be expected to be more vulnerable to them.
May 11, 2026- Could Popular Diabetes and Weight-Loss Drugs Improve Breast Cancer Survival? A New Study Raises Big Questions
A new study published in JAMA Network Open is turning heads in the medical community. It suggests that GLP-1 drugs — the class of medications behind brand names like Ozempic, Wegovy, and Mounjaro — may be linked to dramatically better survival outcomes for women with breast cancer. The findings are exciting, but as with any early research, they come with important caveats worth understanding. Researchers reviewed medical records for more than 841,000 patients diagnosed with breast cancer between 2008 and 2023. Using a statistical technique that matches similar patients to each other (so the comparison is as fair as possible), they created three separate comparison groups: 1,610 breast cancer patients without diabetes who had taken a GLP-1 drug, compared to 1,610 similar patients who hadn’t 2,383 GLP-1 users compared to a matched group taking insulin or metformin (older diabetes drugs) 4,052 GLP-1 users compared to a matched group taking a different newer diabetes drug called an SGLT2 inhibitor
The researchers then tracked two things over 5 and 10 years: how many patients died from any cause, and how many stayed cancer-free (didn’t have their cancer come back). Patients taking GLP-1 drugs had about 60% lower odds of dying from any cause, both at the 5-year and 10-year marks, compared to patients who weren’t taking the drugs. The gap was even bigger when GLP-1 users were compared to patients on insulin or metformin. GLP-1 users were also far more likely to remain cancer-free, compared to both the non-user group and the insulin/metformin group. Interestingly, when GLP-1 users were compared to patients on the SGLT2 inhibitor drugs, there wasn’t a clear difference — at least not until researchers adjusted for other factors, at which point a modest benefit for GLP-1 drugs did appear. According to the doctor who wrote this commentary on the study, no previous research has ever shown a survival benefit this large connected to GLP-1 drugs in breast cancer patients — or in patients with any other type of cancer.
March 15, 2026- New Study Links GLP-1 Drugs to Lower Risk of Addiction — What It Could Mean for Litigation and Regulation
A large new study published in BMJ is adding fuel to an already fast-moving legal and regulatory conversation around GLP-1 receptor agonists — the class of drugs that includes semaglutide (Ozempic, Wegovy) and similar medications. Researchers at the VA Saint Louis Health Care System analyzed health records for more than 600,000 U.S. veterans with type 2 diabetes and found that patients who started a GLP-1 drug were meaningfully less likely to later be diagnosed with a substance use disorder involving alcohol, nicotine, cannabis, cocaine, or opioids, compared with patients started on a different diabetes drug (an SGLT-2 inhibitor). Among veterans who already had a substance use disorder, those on a GLP-1 drug also had lower rates of related ER visits, hospitalizations, overdoses, and deaths. For an industry already facing thousands of product-liability suits over these medications, a study suggesting a protective effect against addiction complicates the litigation narrative in an interesting way.
From a products liability standpoint, this research matters because much of the existing GLP-1 litigation centers on alleged failure-to-warn claims — gastroparesis, bowel obstruction, and similar gastrointestinal injuries are the headline theories. A study documenting a previously undisclosed benefit doesn’t erase those claims, but it could shape how manufacturers frame risk-benefit arguments in Daubert hearings and settlement negotiations going forward. Plaintiffs’ counsel should expect defense experts to cite findings like these to argue that the overall clinical picture for these drugs is more favorable than plaintiffs suggest, even as individual injury claims proceed on their own facts.
There’s also a regulatory dimension worth watching. If follow-up randomized trials confirm what this observational study suggests, it could open the door to expanded or off-label indications for GLP-1 drugs in addiction treatment — an area historically underserved by pharmaceutical innovation. Any such expansion would trigger its own set of legal questions: FDA approval pathways, insurance coverage disputes, and potential liability exposure if the drugs are marketed for addiction treatment before the evidence is fully mature. Health systems and addiction treatment providers considering off-label prescribing in the meantime should be attentive to informed consent documentation, given that this indication remains unapproved and the researchers themselves caution that observational data cannot establish causation.
It’s worth being precise about what this study does and doesn’t show. Because it’s an observational cohort study — not a randomized controlled trial — it can only demonstrate an association, not prove that GLP-1 drugs directly cause a reduction in addiction risk. The authors acknowledge real limitations: the veteran population skews older, male, and white, which may limit generalizability; underdiagnosis of substance use disorders in medical records could affect the numbers; and unmeasured factors like lifestyle or socioeconomic status could still be influencing the results despite extensive statistical adjustment. Attorneys citing this research — on either side of a case — should be careful not to overstate its conclusions, since courts scrutinizing expert testimony will likely probe exactly these caveats.
For now, the practical takeaway for legal practitioners is to treat this as an emerging and legitimate data point rather than a settled fact. It’s unlikely to resolve pending GLP-1 litigation on its own, but it adds another layer to an evidentiary record that plaintiffs, defendants, and regulators alike will be drawing on as this drug class continues to reshape both medicine and mass tort practice. Firms handling GLP-1 cases — whether on the plaintiff or defense side — should be tracking this line of research closely, since the scientific narrative around these drugs is still very much in motion.
March 14, 2026- Stopping Ozempic or Mounjaro May Not Mean Regaining the Weight — New Study Offers a More Hopeful Picture
For years, the assumption around drugs like Ozempic and Mounjaro has been simple: stop taking them, and the weight comes back. That belief was based mainly on clinical trials, where patients had no other option once they stopped the medication. A new study from Cleveland Clinic, looking at nearly 8,000 real-world patients, tells a different story. Most people who stopped these drugs did not regain most of their lost weight within a year. Many simply switched to another treatment, went back on the same medication later, or leaned on lifestyle support like diet and exercise coaching — and that flexibility appears to have made a real difference.
For lawyers who work on health, insurance, or product liability matters, this distinction between clinical-trial results and real-world outcomes is worth paying attention to. The study found that cost and insurance coverage were the biggest reasons people stopped these drugs in the first place — not because the drugs stopped working or because patients gave up. That points to insurance coverage, not drug safety or effectiveness, as the real barrier for many patients. As more insurance disputes and coverage denials involving weight-loss drugs work their way through appeals, arbitration, or litigation, real-world data like this could become useful evidence that continued or restarted treatment is both effective and reasonable to expect.
It’s also a good reminder that not all evidence is created equal. This was a retrospective look at real patient records, not a randomized controlled trial, so it can show patterns but can’t prove that any one factor — a new medication, a lifestyle program, or something else — caused the better outcomes. Still, for attorneys advising clients on insurance appeals, employer health benefit disputes, or even personal injury cases touching on these drugs, this kind of real-world data offers a more accurate, everyday picture than trial results alone. As GLP-1 drugs remain a hot topic in both medicine and law, expect more real-world studies like this one to shape how these cases are argued and decided.
March 2, 2026- New Meta-Analysis Finds GLP-1 Weight-Loss Drugs Work Consistently Across Groups — With One Notable Exception
A new meta-analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health, published March 2 in JAMA Internal Medicine, offers data that health and product liability practitioners handling GLP-1 receptor agonist (GLP-1 RA) matters will want on their radar. The researchers pooled results from 64 clinical trials covering semaglutide (Ozempic), dulaglutide (Trulicity), and related drugs, and found that effectiveness for weight loss was statistically similar across age groups, racial and ethnic groups, starting BMI, and starting blood sugar levels. The one significant exception was sex: women lost an average of roughly 11% of their starting body weight, compared to roughly 7% for men — a gap the authors attribute to possible hormonal interactions, differences in drug metabolism, and lower median starting body weight among women, rather than to any flaw in trial design or patient selection.
For counsel, this study is a useful evidentiary data point on two fronts. First, in product liability or failure-to-warn litigation, a finding of consistent effectiveness across race, ethnicity, age, and starting weight undercuts theories premised on differential efficacy or inadequate testing across demographic subgroups — while the documented sex-based difference in outcomes is the kind of finding that could support (or need to be addressed in) warning label and informed consent arguments going forward. Second, in coverage and reimbursement disputes, payors and plan administrators may look to data like this to justify or challenge prior authorization criteria that don’t currently account for sex-based differences in expected outcomes, and counsel on either side should be prepared to engage with the underlying subgroup analyses rather than the headline effect size alone.
As with any meta-analysis, the underlying trials varied in size and design, and the researchers themselves frame this as an early step toward better understanding how GLP-1 RAs perform across real-world patient populations — particularly those historically underrepresented in industry-sponsored trials. Notably, the analysis excluded tirzepatide (Zepbound), since it acts on an additional hormone pathway (GIP) not captured by this study, so its findings should not be extended to that drug without caveat. Given the drugs’ cost, popularity, and expanding approved uses — from obesity and type 2 diabetes to cardiovascular risk reduction — expect this kind of subgroup evidence to feature increasingly in litigation, regulatory comment, and coverage disputes involving this drug class.
February 20, 2026 – Ozempic May Help Ease Osteoarthritis Symptoms
New findings suggest that Ozempic could play a role in improving joint health. Research published in Cell Metabolism indicates that semaglutide may help increase cartilage thickness in joints affected by osteoarthritis. Increased cartilage can provide better cushioning between bones, potentially reducing friction, limiting bone-on-bone contact, and alleviating joint pain.
February 12, 2026 – Study Examines Vision Risks Linked to Semaglutide
A large-scale analysis conducted within the Veterans Health Administration reviewed patient data from March 2018 through March 2025. Researchers compared individuals prescribed GLP-1 medications such as Wegovy, Ozempic, and Rybelsus against patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2i), including Jardiance, Farxiga, and Invokana.
Led by Dr. Kent Heberer, the study evaluated over 102,000 veterans and found that patients starting semaglutide had roughly double the rate of developing Nonarteritic Anterior Ischemic Optic Neuropathy compared to those on SGLT2 inhibitors.
“In this nationwide cohort of US veterans with T2D, semaglutide initiators had a 2-fold NAION risk than SGLT2i initiators, while the absolute risk was low. Clinicians and patients should be counseled on the rare but evident increased risk of NAION after semaglutide initiation.”
– Dr. Kent Heberer
January 8, 2026 – Rapid Weight Regain After Discontinuing GLP-1 Drugs
Evidence shows that individuals who stop GLP-1 weight-loss medications often regain weight more quickly than those who discontinue diet or exercise programs alone. About half of patients discontinue these medications within a year, commonly due to cost or gastrointestinal side effects.
A review published in BMJ analyzed data from over 6,000 individuals using GLP-1 therapies and compared them with 3,000 participants in lifestyle-based weight-loss programs. The findings revealed that patients regained nearly one pound per month on average after stopping medication, with many regaining approximately 10 pounds within a year.
Researchers also estimated that improvements in cholesterol, blood pressure, and diabetes risk markers could return to pre-treatment levels within two years. Sam West noted that weight regain occurred significantly faster—nearly four times quicker—than in individuals who stopped diet or exercise interventions.
November 23, 2025 – Gastrointestinal Risks Across GLP-1 Medications
A major study published in Annals of Internal Medicine found that GLP-1 receptor agonists share similar gastrointestinal safety profiles. Researchers from Brigham and Women’s Hospital and Harvard Medical School analyzed over 200,000 patient records.
The study, led by Dr. Elizabetta Patorno, compared semaglutide, tirzepatide, and Trulicity with SGLT-2 inhibitors such as Januvia and Farxiga.
Results showed similar risks among GLP-1 drugs for serious gastrointestinal complications, including gastroparesis, pancreatitis, and bowel obstruction requiring emergency care. However, these medications were associated with higher overall GI risks compared to SGLT-2 inhibitors.
Ozempic users had about a 21% increased risk, while Trulicity users faced over a 35% increase. Mounjaro was linked to the highest risk, with nearly a 49% increase in severe gastrointestinal complications.
October 27, 2025 – Conflicting Eye Health Findings Presented at Ophthalmology Conference
At the annual meeting of the American Academy of Ophthalmology, researchers presented two studies with differing conclusions about GLP-1 medications.
The first study, based on global safety data from the World Health Organization, reviewed over 117,000 patients and found that GLP-1 users had significantly higher rates of NAION and diabetic retinopathy compared to those taking other diabetes treatments.
A second study, conducted at the Cleveland Clinic Cole Eye Institute, analyzed more than 430,000 patients aged 50 and older. It found that long-term GLP-1 use was associated with a substantially lower risk of developing dry age-related macular degeneration (AMD), though no protective effect was observed for the wet form of the disease.
These contrasting results highlight ongoing uncertainty about how these medications impact eye health.
October 10, 2025 – Possible Kidney Risks Under Investigation
A preliminary report suggested a potential link between GLP-1 drugs like Ozempic and Wegovy and acute kidney injury. However, the study relied on adverse event reports submitted to the FDA and has not undergone peer review, making the findings less reliable. Notably, similar associations were not observed with Mounjaro or Zepbound.
July 29, 2025 – Study Suggests Link to Retinal Vein Occlusion
Researchers in Sweden reported a possible association between semaglutide use and retinal vein occlusion, a serious condition that can cause sudden vision loss.
Original Clinical Trial Data
Ozempic clinical trials primarily focused on:
- A1C reduction
- blood sugar stability
- weight change
- cardiovascular outcomes
Most trials lasted only 6–12 months, meaning long-term organ safety data is limited.
During early trial periods, common adverse effects were:
- nausea
- vomiting
- diarrhea
- constipation
- appetite reduction
Researchers noted slowed gastric emptying as a known drug mechanism — long before severe motility injury reports began appearing post-approval.
FDA Safety Monitoring & Post-Market Signals
After Ozempic entered widespread use, regulators began receiving increasing reports of:
- gastroparesis
- chronic vomiting
- intestinal obstruction
- pancreatitis
- gallbladder disease
- kidney injury
These signals prompted ongoing safety-monitoring efforts involving:
- MedWatch submissions
- physician reporting
- hospital data
- post-marketing surveillance
While not every reported complication proves causation, patterns have emerged that researchers continue to track.
Research on Gastroparesis & GI Motility Disorders
Multiple reviews and clinical observations suggest that semaglutide’s effect on gastric emptying may trigger pathological motility disorders in some users.
Findings include:
- slowed digestion beyond therapeutic expectation
- increased gastric retention times
- impaired stomach muscle contractility
- prolonged nausea and vomiting lasting months
- symptomatic cases persisting after drug discontinuation
Gastroparesis is now one of the most widely reported severe digestive outcomes associated with Ozempic.
Research on Pancreatitis Risk
Pancreatic inflammation was flagged early in GLP-1 drug research and remains an active area of investigation.
Key findings from case reports and hospital data:
- pancreatitis has occurred in some Ozempic users
- many cases appear after dose escalation
- vomiting and gallbladder complications may heighten risk
- some patients develop chronic inflammation or recurrence
Kidney Injury & Dehydration-Linked Renal Decline
Published medical cases have described Ozempic users experiencing:
- acute kidney injury
- repeated dehydration episodes
- persistent kidney function loss
- need for hospitalization or monitoring
Vomiting, electrolyte loss, and reduced food/fluid intake appear to be major drivers.
Gallbladder Studies Related to Rapid Weight Loss
Research shows rapid weight loss is strongly associated with:
- gallstone formation
- gallbladder inflammation
- bile duct blockages
- gallbladder removal surgery
Because Ozempic often produces rapid weight loss — especially at high or escalating doses — researchers are closely tracking gallbladder outcomes.
Black Box Warning Research: Thyroid Tumor Risk
Animal studies triggered the FDA’s Black Box Warning involving:
- thyroid C-cell proliferation
- tumor development
- Medullary Thyroid Carcinoma (MTC)
Human data remains incomplete. Some researchers argue risk is lower than rodent models suggest; others caution that long-term data is insufficient.
Long-Term Data Gaps Identified by Researchers
Key unanswered safety questions include:
- Does extended Ozempic use permanently alter GI motility?
- What percentage of gastroparesis cases are irreversible?
- How does repetitive vomiting impact kidney function over years?
- Could pancreatic inflammation progress with long-term use?
- What cumulative gallbladder risks emerge after 3–5 years?
- Does thyroid tumor risk increase after decade-scale exposure?
The absence of long-range clinical trials leaves these questions unresolved.
➡️ Long-Term Effects of Ozempic
Case Reports, Hospital Data & Physician Observations
Clinicians have published and described cases involving:
- chronic gastric paralysis
- intestinal blockage
- severe malnutrition
- pancreatic injury requiring treatment
- kidney failure after dehydration
Many involve patients initially presenting with persistent nausea and vomiting.
Patterns seen in reports:
- symptoms beginning shortly after dose increases
- complications appearing after months of use
- long-term residual damage even after stopping the drug
Regulatory Scrutiny & Global Review
Countries including the U.S., Canada, and the EU have:
- reviewed adverse-event data
- updated warnings
- monitored gastrointestinal and pancreatic risks
- issued advisories for high-risk patients
Research is expected to expand as prescription volume continues to rise.
Critical Research Priorities Going Forward
Medical researchers widely agree on the need for:
- multi-year follow-up studies
- pancreatic injury surveillance
- kidney-function trend analysis
- GI motility outcome tracking
- gallbladder surgery data
- thyroid-monitoring studies
- metabolic rebound research post-discontinuation
As many patients now use Ozempic indefinitely, long-term science remains urgent.
What Research Means for Patients
Patients using Ozempic long-term should:
- monitor symptoms
- report persistent nausea or vomiting
- track kidney labs
- seek immediate care if abdominal pain develops
- consult physicians before adjusting doses
- discuss long-term risk unknowns
Early recognition is key to preventing permanent outcomes.
Legal Rights & Research Implications
Emerging research has become central in legal claims alleging injury from Ozempic use. While studies continue, medical records and diagnostic findings often guide eligibility.
You may qualify for a claim if you experienced:
- gastroparesis
- pancreatitis
- kidney injury
- gallbladder disease
- intestinal obstruction
- long-term digestive impairment
➡️ Case review links:
👉 Ozempic Lawsuits
👉 GLP-1 Drug Litigation
Related Information
- Ozempic Side Effects
- Long-Term Effects
- Pancreatitis Risk
- Kidney Problems
- Gastroparesis
- Black Box Warnings
Ozempic research is still unfolding. Early trials showed strong metabolic benefits, but post-marketing data, case reports, and clinical observations highlight concerns ranging from chronic gastric paralysis to pancreatitis, kidney injury, gallbladder disease, and unanswered long-term safety questions. Because no long-duration safety trials exist yet, researchers continue to study potential risks — especially in patients using Ozempic at high doses or for extended periods.
If Ozempic use resulted in serious complications, medical and legal options may be available.